Invention Grant
- Patent Title: N-11 truncated amyloid-beta monoclonal antibodies, compositions, methods and uses
-
Application No.: US15142075Application Date: 2016-04-29
-
Publication No.: US09939452B2Publication Date: 2018-04-10
- Inventor: Marc Hubert Mercken , Marc Maria Pierre Vandermeeren
- Applicant: Janssen Pharmaceutica NV
- Applicant Address: BE
- Assignee: JANSSEN PHARMACEUTICA NV
- Current Assignee: JANSSEN PHARMACEUTICA NV
- Current Assignee Address: BE
- Priority: WOPCT/EP02/11062 20020927
- Main IPC: A61K39/395
- IPC: A61K39/395 ; A61K39/00 ; A61K49/00 ; A61K49/16 ; C07K16/00 ; C12P21/08 ; G01N33/53 ; G01N33/68 ; C07K16/18
Abstract:
This invention relates to antibodies, including specified portions or variants, specific for at least the human Amyloid-beta_11 N-terminal site, i.e. Aβ11-x peptides. It further provides methods of making and using said antibodies, including therapeutic formulations, administration and devices.
Public/Granted literature
- US20170192016A1 N-11 TRUNCATED AMYLOID-BETA MONOCLONAL ANTIBODIES, COMPOSITIONS, METHODS AND USES Public/Granted day:2017-07-06
Information query
